NCT01532700View on ClinicalTrials.gov

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
DRUG

Ofatumumab with GSK2110183

"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"

Trial Locations (1)

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT01532700 - An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter